These findings provide new insights on the understanding of the cause of less effectiveness of IFN-α therapy in HCC and helpful to develop new combination therapeutic strategy for treating cancers with IFN-α in clinical practice. Here, IFNA1 is linked to hepatocellular carcinoma.